Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
Eli Lilly’s first successful Phase 3 retatrutide readout came from TRIUMPH-4, a 68-week study in adults with obesity or overweight and knee osteoarthritis. This 2026 research update explains the topline results, trial design, triple-agonist mechanism, weight and knee-pain findings, safety context, limitations, and what the data mean for retatrutide research in Canada.
TRIUMPH-4 is the first successful Phase 3 topline readout for retatrutide, also known as LY3437943. Lilly reported that adults with obesity or overweight and knee osteoarthritis receiving retatrutide 12 mg lost an average of 28.7% of body weight at 68 weeks, equal to up to 71.2 lb on average, while also showing statistically significant improvement in knee osteoarthritis pain and physical function. These are sponsor-reported topline results, and full peer-reviewed trial data remain important for final interpretation.
Retatrutide is an investigational triple hormone receptor agonist designed to activate the GIP receptor, GLP-1 receptor, and glucagon receptor. TRIUMPH-4 matters because it is the first Phase 3 readout from Lilly’s broader retatrutide development program and provides late-stage clinical research context for the compound’s metabolic and musculoskeletal outcome profile.
TRIUMPH-4 studied retatrutide in adults with obesity or overweight and knee osteoarthritis. The key topline finding was large average weight reduction at 68 weeks, combined with meaningful improvement in knee pain and physical function measures. Because the results are topline sponsor data, they should be interpreted as an important research milestone, not as a final peer-reviewed clinical paper.
The study also gives researchers a clearer view of how triple agonism may extend beyond body-weight research into joint-load, pain, mobility, cardiovascular risk marker, and broader metabolic outcome models.
TRIUMPH-4 was designed to evaluate retatrutide in a population where weight reduction and knee osteoarthritis outcomes are clinically and mechanistically connected.
| Trial Feature | TRIUMPH-4 Details | Research Interpretation |
|---|---|---|
| Compound | Retatrutide, also known as LY3437943 | Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. |
| Study phase | Phase 3 | Late-stage clinical research readout. |
| Duration | 68 weeks | Long enough to assess sustained body-weight and knee-pain outcome trends. |
| Population | Adults with obesity or overweight and knee osteoarthritis | Important because weight change can affect mechanical load, pain, and function. |
| Comparator | Retatrutide once weekly versus placebo | Allows interpretation against a placebo control within the trial design. |
| Key endpoints | Body-weight change, knee osteoarthritis pain, and physical function measures | Connects metabolic outcomes with mobility and joint-function research. |
Lilly’s December 2025 topline release reported substantial body-weight reduction and knee osteoarthritis improvements in the highest-dose retatrutide group.
| Outcome Area | Topline Finding | Research Interpretation |
|---|---|---|
| Body weight | Retatrutide 12 mg was reported to produce 28.7% average body-weight reduction at 68 weeks among treatment-adherent participants. | Places retatrutide among the most closely watched investigational metabolic compounds in late-stage obesity research. |
| Absolute weight change | The highest-dose group was reported to lose up to an average of 71.2 lb, or 32.3 kg. | Provides a concrete magnitude for interpreting the topline result. |
| Knee osteoarthritis pain | All primary and key secondary endpoints were reported as met, including knee osteoarthritis pain improvement. | Connects metabolic weight-change research with joint-pain and mobility outcome research. |
| Physical function | Physical function scores were reported to improve significantly versus placebo. | Important for interpreting the trial beyond weight alone. |
| Cardiometabolic markers | Favorable changes were reported in markers such as non-HDL cholesterol, triglycerides, and systolic blood pressure. | Supports broader cardiometabolic research interest, while full data remain important. |
Retatrutide is different from single GLP-1 agonists and dual GIP / GLP-1 agonists because it adds glucagon receptor agonism. That third receptor pathway is the defining scientific feature of the compound.
| Receptor Pathway | Research Role | Why It Matters in Retatrutide Research |
|---|---|---|
| GLP-1 receptor | Glucose, satiety-related signaling, gastric and metabolic pathway research | Connects retatrutide to established GLP-1 receptor agonist research. |
| GIP receptor | Insulinotropic signaling, adipose biology, and incretin interaction research | Connects retatrutide to dual-incretin models such as tirzepatide comparisons. |
| Glucagon receptor | Energy expenditure, hepatic lipid metabolism, and liver-fat biology | The added pathway that makes retatrutide a triple agonist rather than a dual agonist. |
| Integrated model | Multi-receptor metabolic signaling | Allows research into whether three receptor pathways produce different effects than one or two pathways alone. |
Semaglutide is mainly the GLP-1 model. Tirzepatide is the GIP plus GLP-1 model. Retatrutide is the GIP plus GLP-1 plus glucagon model. That third glucagon pathway is why retatrutide is being studied for energy-balance, liver-fat, and broader cardiometabolic effects beyond standard GLP-1-only comparisons.
Lilly described the TRIUMPH-4 safety profile as generally consistent with prior retatrutide research and the broader incretin-based therapy class. Full peer-reviewed safety tables remain important for final interpretation.
| Safety Area | Topline Context | Research Interpretation |
|---|---|---|
| Common adverse events | Reported events were primarily gastrointestinal, including nausea, diarrhea, vomiting, constipation, and reduced appetite. | Consistent with the broader incretin-based research category. |
| Discontinuations | Some participants discontinued because of adverse events or concern around rapid weight reduction. | Important for interpreting tolerability, dose selection, and long-term study design. |
| Weight-loss magnitude | High magnitude of weight change was central to both efficacy and tolerability interpretation. | Large body-weight changes require careful endpoint and safety interpretation. |
| Final interpretation | Full peer-reviewed data and regulatory review remain important. | Topline releases are not a substitute for full trial publication. |
TRIUMPH-4 is a major retatrutide milestone, but careful interpretation matters. Topline clinical research results should not be converted into broad claims or instructions for research materials.
| What TRIUMPH-4 Supports | What It Does Not Prove |
|---|---|
| Retatrutide has late-stage clinical research evidence in adults with obesity or overweight and knee osteoarthritis. | It does not mean retatrutide is approved for consumer use. |
| Triple agonism is a serious late-stage metabolic research strategy. | It does not prove all triple agonists will behave the same way. |
| Weight change, knee pain, and physical function can be studied together in this population. | It does not provide dosing guidance for research-use materials. |
| Cardiometabolic marker changes were directionally favorable in the topline report. | It does not replace cardiovascular outcome trials or full peer-reviewed analysis. |
| More Phase 3 readouts are expected across the broader retatrutide program. | It does not guarantee future regulatory approval or final label outcomes. |
Retatrutide is a complex investigational peptide used in precise receptor-signaling and metabolic research contexts. Documentation quality matters for reproducible research interpretation.
| Standard | Why It Matters |
|---|---|
| High-purity expectation | Supports cleaner interpretation in GLP-1R, GIPR, GCGR, glucose, liver-fat, and metabolic signaling models. |
| Batch-specific COA | Improves lot-level traceability and repeatability between research runs. |
| HPLC verification | Provides analytical support for purity claims. |
| Mass spectrometry confirmation | Supports molecular identity verification. |
| Clear research-use-only labeling | Keeps the material separated from consumer, clinical, therapeutic, obesity, diabetes, weight-loss, or human-use positioning. |
These answers cover the most common TRIUMPH-4 and retatrutide Phase 3 research questions in 2026.
TRIUMPH-4 is a Phase 3 clinical study evaluating once-weekly retatrutide in adults with obesity or overweight and knee osteoarthritis. It is the first successful Phase 3 topline readout from Lilly’s broader retatrutide program.
Lilly reported that participants receiving retatrutide 12 mg lost an average of 28.7% of body weight at 68 weeks among treatment-adherent participants, equal to up to an average of 71.2 lb, or 32.3 kg.
Lilly reported statistically significant improvements in knee osteoarthritis pain and physical function scores compared with placebo. Full peer-reviewed data remain important for final interpretation.
Retatrutide activates GIP, GLP-1, and glucagon receptor pathways. This triple-agonist model lets researchers study whether adding glucagon receptor activity changes metabolic, energy-expenditure, liver-fat, and cardiometabolic outcomes compared with single or dual agonist models.
No. Retatrutide remains investigational. This page discusses retatrutide strictly in a research and clinical-trial context and does not present it as approved for human, veterinary, diagnostic, or therapeutic use.
The December 2025 TRIUMPH-4 results were sponsor-reported topline results. A full peer-reviewed publication, complete statistical analysis, and full safety tables remain important for final interpretation.
Researchers should look for batch-specific COAs, HPLC purity documentation, mass-spectrometry identity confirmation, clear lot numbers, proper storage guidance, and research-use-only labeling.
Luxara Labs provides Canadian fulfillment, USA-facing research resources, documentation support, and shipping guidance for North American researchers evaluating retatrutide as a research-use-only material.
These references support the retatrutide, TRIUMPH-4, Phase 3, triple agonist, obesity, knee osteoarthritis, GLP-1, GIP, glucagon receptor, MASLD, and clinical-trial context discussed on this page.
Join our list and get an instant 10% discount code — valid for first-time buyers.
